TABLE 1.
Characteristics of participants included in analysis of relative effectiveness of a booster dose of COVID‐19 vaccination versus two‐dose primary series by booster and infection status: Prospective Assessment of COVID‐19 in a Community (PACC) study December 20, 2021–July 28, 2022.
| Booster vaccinated a | Primary series vaccinated ≥5 months b | |||||
|---|---|---|---|---|---|---|
| SARS‐CoV‐2 Infected c no. (%) | SARS‐CoV‐2 Uninfected c no. (%) | Total no. (%) | SARS‐CoV‐2 Infected c no. (%) | SARS‐CoV‐2 Uninfected c no. (%) | Total no. (%) | |
| Age Group (years) | ||||||
| 5–11 | 1 (0.8) | 9 (1.8) | 10 (1.6) | 17 (17.5) | 34 (21.1) | 51 (19.8) |
| 12–17 | 5 (4.2) | 24 (4.7) | 29 (4.6) | 16 (16.5) | 30 (18.6) | 46 (17.8) |
| 18–49 | 47 (39.8) | 121 (23.9) | 168 (26.9) | 41 (42.3) | 49 (30.4) | 90 (34.9) |
| 50–64 | 31 (26.3) | 105 (20.7) | 136 (21.8) | 17 (17.5) | 36 (22.4) | 53 (20.5) |
| ≥65 | 34 (28.8) | 248 (48.9) | 282 (45.1) | 6 (6.2) | 12 (7.5) | 18 (7.0) |
| Sex | ||||||
| Female | 69 (58.5) | 312 (61.5) | 381 (61.0) | 65 (67.0) | 89 (55.3) | 154 (59.7) |
| Male | 49 (41.5) | 195 (38.5) | 244 (39.0) | 32 (33.0) | 72 (44.7) | 104 (40.3) |
| Chronic Condition(s) d | ||||||
| Yes | 61 (51.7) | 326 (64.3) | 387 (61.9) | 35 (36.1) | 69 (42.9) | 104 (40.3) |
| No | 57 (48.3) | 181 (35.7) | 238 (38.1) | 62 (63.9) | 92 (57.1) | 154 (59.7) |
| Immune Compromised e | ||||||
| Yes | 8 (6.8) | 39 (7.7) | 47 (7.5) | 4 (4.1) | 5 (3.1) | 9 (3.5) |
| No | 110 (93.2) | 468 (92.3) | 578 (92.5) | 93 (95.9) | 156 (96.9) | 249 (96.5) |
| Prior SARS‐CoV‐2 Infection f | ||||||
| Yes | 20 (16.9) | 174 (34.3) | 194 (31.0) | 33 (34.0) | 97 (60.2) | 130 (50.4) |
| No | 98 (83.1) | 333 (65.7) | 431 (69.0) | 64 (66.0) | 64 (39.8) | 128 (49.6) |
Receipt of three doses of SARS‐CoV‐2 messenger RNA vaccine. Individuals are considered boosted ≥14 days after receipt of their third dose.
Receipt of two doses of SARS‐CoV‐2 messenger RNA vaccine and eligible for booster dose.
SARS‐CoV‐2 infection status during the follow‐up period December 20, 2021–July 28, 2022.
At enrollment, participants were asked to report any of the following chronic conditions: asthma, cancer, chronic kidney disease, COPD, hypertension, immunocompromised state, serious heart condition (heart failure, coronary artery disease or cardiomyopathies), or Type 2 diabetes.
Immune compromised state self‐reported by study participant at enrollment.
SARS‐CoV‐2 infection prior to December 20, 2021 or person‐time entry, whichever is later.